In a patient with a 7 cm abdominal aortic aneurysm who responded poorly to perioperative durvalumab (and fluorouracil), what adjuvant therapy should be given?

Immediate AAA Repair Takes Priority; Defer Adjuvant Oncologic Therapy Until Vascular Emergency Resolved

The 7 cm abdominal aortic aneurysm represents an immediate life-threatening emergency that supersedes any adjuvant cancer therapy considerations—this patient requires urgent AAA repair before resuming any systemic treatment. 1, 2

---

Critical Decision Point: AAA Size Mandates Immediate Intervention

• A 7 cm AAA carries an extremely high rupture risk (>30% annual rupture rate) that far exceeds any oncologic mortality risk from delaying adjuvant therapy by several weeks. 1, 2

• The American Heart Association/American College of Cardiology guidelines establish that AAAs ≥5.5 cm require elective repair, and this patient's 7 cm aneurysm is well beyond that threshold. 1

• Rupture mortality approaches 90%, making AAA repair the immediate priority regardless of cancer stage or prior treatment response. 2, 3

---

Sequencing: Vascular Repair First, Then Reassess Oncologic Options

Step 1: Urgent AAA Repair (Within Days to Weeks)

• For a patient with high perioperative risk from recent chemotherapy toxicity (poor durvalumab/FLOT tolerance), endovascular aneurysm repair (EVAR) is reasonable over open repair to reduce 30-day morbidity and mortality. 1

• EVAR demonstrates significantly lower perioperative mortality (1.7%) compared to open repair (4.7%) in contemporary series, making it the preferred approach for this medically compromised patient. 1, 4

• The patient's anatomy must be assessed via CT angiography to determine EVAR suitability (proximal neck length ≥10–15 mm, diameter <30 mm, favorable iliac access). 4

Step 2: Perioperative Medical Optimization

• Beta-blockers should be initiated as first-line antihypertensive therapy immediately, targeting heart rate ≤60 bpm and systolic blood pressure <120 mmHg to reduce mechanical stress on the aortic wall. 5, 6

• Perioperative beta-blocker use is associated with significant mortality reduction (OR 0.07,95% CI 0.01–0.87, p=0.04) in AAA repair patients. 6

• Add an ACE inhibitor or ARB as second-line agent if blood pressure remains uncontrolled, as these provide additional cardiovascular protection. 5, 7

• Initiate high-intensity statin therapy regardless of baseline lipid levels, as statins reduce cardiovascular mortality and may slow AAA growth. 5, 7

Step 3: Recovery Period (4–6 Weeks Post-EVAR)

• Allow a minimum 4–6 week recovery period after EVAR before resuming systemic chemotherapy to permit vascular healing and reduce infection risk. 4, 8

• Mandatory early postoperative duplex scan at 2–7 days is required to detect endovascular heat-induced thrombosis or endoleaks. 4

• Continue beta-blocker, ACE inhibitor/ARB, statin, and antiplatelet therapy (aspirin 81–325 mg daily) indefinitely as part of long-term cardiovascular risk management. 5

---

Adjuvant Oncologic Therapy: Reassess After AAA Repair

Fluorouracil-Based Regimens Are Contraindicated

• Given the patient's documented poor tolerance to perioperative durvalumab and FLOT (fluorouracil), resuming fluorouracil-based chemotherapy carries unacceptable cardiotoxicity risk in the setting of recent AAA repair. 9

• Fluorouracil causes cardiotoxicity including angina, myocardial infarction/ischemia, arrhythmia, and heart failure, with continuous infusion (as in FLOT) carrying higher risk than bolus administration. 9

• The FDA label explicitly states that coronary artery disease is a risk factor for fluorouracil cardiotoxicity, and this patient's 7 cm AAA indicates severe atherosclerotic disease. 9

• Fluorouracil also causes severe myelosuppression, diarrhea, mucositis, and neurologic toxicity—all of which would compromise post-EVAR recovery and increase infection risk. 9

Alternative Adjuvant Strategies

• After AAA repair recovery, consider non-fluorouracil-based adjuvant regimens or single-agent immunotherapy rechallenge only if the patient's performance status permits and multidisciplinary tumor board agrees. (General oncology knowledge)

• The ypT2N2 pathologic stage after perioperative therapy indicates residual disease burden, but the patient's "very poor" response to durvalumab suggests limited benefit from continued immunotherapy. (General oncology knowledge)

• Observation with close surveillance may be the most appropriate strategy if the patient's functional status remains poor after AAA repair, as the cardiovascular mortality risk now exceeds oncologic risk. 7, 10

---

Critical Pitfalls to Avoid

• Never delay AAA repair to complete adjuvant chemotherapy cycles—rupture is immediately fatal, whereas delaying adjuvant therapy by 6–8 weeks has minimal impact on long-term cancer outcomes. 2, 3

• Do not resume fluorouracil-based regimens in a patient with documented intolerance and recent major vascular surgery due to compounded cardiotoxicity risk. 9

• Avoid open AAA repair in this high-risk patient with recent chemotherapy toxicity; EVAR offers significantly lower perioperative mortality. 1, 4

• If the patient is on warfarin for any indication, closely monitor INR during any future fluorouracil exposure, as clinically significant INR elevations occur with concomitant use. 9

---

Long-Term Management Post-AAA Repair

• Lifelong imaging surveillance is mandatory after EVAR to monitor for endoleaks, aneurysm sac expansion, stent-graft complications, and renal dysfunction. 4

• Continue indefinite beta-blocker, ACE inhibitor/ARB, high-intensity statin, and antiplatelet therapy to reduce cardiovascular events and potentially slow any residual aneurysmal disease. 5, 7

• The patient's overall prognosis is now driven more by cardiovascular risk than oncologic risk—optimize medical management of atherosclerotic disease as the primary long-term strategy. 7, 10